The Zhitong Finance App learned that CMB International released a research report stating that the target price of China Biopharmaceuticals (01177) was raised by 3.4% from HK$8.7 to HK$9, maintaining the “buy” rating. Considering that the company continues to fulfill BD transactions in 2026, the bank raised its forecast. Revenue is expected to increase 11.5%, 13.2% and 10.4% year-on-year in 2026, 2027 and 2028, respectively, and adjusted net profit to mother will increase by 12.5%, 19.4%, and 9.9%, respectively.
The bank pointed out that recently, Chinese biopharmaceuticals have continued to make breakthroughs in both commercialization and internationalization of innovative drugs. On November 14, 2026, the National Health Insurance Administration announced the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2026)”. The core Chinese biopharmaceutical company, Zhengda Tianqing, included 3 innovative drugs in the catalogue for the first time, 2 new indications of innovative drugs were included in the catalogue, and 2 innovative drugs were successfully renewed.
Furthermore, the company recently reached a platform-based BD cooperation with multinational pharmaceutical company Boehringer Ingelheim (BI), involving a down payment of US$358 million and recent payments, with a total potential amount of about US$7 billion and a double-digit sales share, continuing the strong trend of the company's foreign cooperation in 2026. The bank believes that the expansion of medical insurance is expected to accelerate the commercial transformation of the company's innovative products, while cooperation with BI will verify the value of the company's early research platform and consolidate the foundation for long-term growth of the innovative business.